Abstract
The efficacy of single site, intradermal human diploid cell rabies vaccine (HDCV) was assessed in patients exposed to rabies, who were treated at a rural mission hospital in central Thailand. Intradermal HDCV, 0·1 ml on days 0, 3, 7 and 14, resulted in protective antibody levels by day 14, with measurable titres present at one year. 98% of 219 patients completed primary vaccination and 84% returned for a one-year booster. No case of rabies has been seen in those vaccinated. Intradermal HDCV in small doses has given results superior to those from vaccination with nervous tissue vaccine with conventional schedules. This intradermal HDCV regimen has proved acceptable to patients, and is suitable for post-rabies-exposure care in developing countries where low cost is essential.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
